You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Jeffery Edward Arambel (Bankr. E.D. Cal. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Jeffery Edward Arambel
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Details for Jeffery Edward Arambel (Bankr. E.D. Cal. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-01-17 External link to document
2018-01-17 861 Disclosure Statement / Ch. 11 Disclosure Stmt / Red-Lined - Including Amended Estimated Amolunt of Unsecured Claims 10,555,993 …Documents and General Intangibles (including all patents, patent applications, trademarks, trademark… Grants of Security Interest in Trademarks and Patents and Grants of Security Interest in Copyrights External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Jeffery Edward Arambel (Case 18-90029)

Last updated: February 23, 2026

What Are the Key Details of the Case?

Jeffery Edward Arambel's litigation case (18-90029) involves federal securities regulation. The case appears in the U.S. District Court, Central District of California, and pertains to allegations of securities law violations. The case was filed on April 29, 2018. The case number indicates a federal civil matter.

What Are the Main Allegations?

The complaint alleges that Arambel engaged in fraudulent activities related to securities offerings, specifically involving misstatement or omission of material information to investors. The allegations specify violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5.

What Are the Parties' Positions?

  • Plaintiff: The Securities and Exchange Commission (SEC) alleges Arambel knowingly or recklessly made false statements that influenced investor decisions, which resulted in financial harm.
  • Defendant: Arambel denies misconduct, asserting that any statements made were based on reasonable belief and lacked fraudulent intent. He also contests the factual basis of the allegations.

What Is the Litigation Timeline?

  • April 29, 2018: Complaint filed.
  • June 2018: Defendant filed a motion to dismiss.
  • December 2018: Court issued an order denying the motion in part and granting in part.
  • May 2020: Court scheduled trial proceedings.
  • March 2021: Settlement discussions initiated but no resolution reported as of December 2022.
  • Latest Update: Case status pending with continued negotiations or possible further motions.

How Does This Compare to Similar Cases?

Most securities fraud cases litigated under Sections 10(b) and 20(a) involve allegations of misstatements or omissions material to investors. Typical resolution includes settlement or court judgment. Arambel’s case reflects a pattern where the SEC pursues individuals directly involved in fraudulent conduct.

What Are the Potential Outcomes?

  • Judicial ruling: Court may find in favor of the SEC, resulting in civil penalties, disgorgement, or injunctions.
  • Settlement: Parties may reach an agreement on sanctions or remedial measures.
  • Dismissal: Court may dismiss the case if evidence fails to establish fraudulent intent or materiality.

What Are the Financial and Regulatory Implications?

The case acts as a precedent for enforcement actions against individual actors in securities violations. It emphasizes issuers' and involved individuals' accountability for disclosures. Penalties can range from monetary fines to bans from serving as officers or directors.

Summary of Litigation Status

Date Event Outcome
April 29, 2018 Complaint filed Initiates litigation
June 2018 Motion to dismiss filed Pending court ruling
December 2018 Court opinion issued Partial denial/approval
May 2020 Trial scheduled Pending or postponed
March 2021 Settlement negotiations Ongoing or unresolved
December 2022 Status update available Pending further developments

Key Takeaways

  • The case involves allegations of securities fraud under federal law, with allegations focused on misstatements related to offerings.
  • The litigation process has involved motions and ongoing negotiations; no final resolution reported.
  • Penalties, if any, will depend on court findings but could include monetary sanctions and disqualification from securities activities.
  • The case exemplifies enforcement against individual misconduct in securities transactions.
  • Record-keeping, disclosure accuracy, and responsible conduct remain critical compliance issues.

Frequently Asked Questions

  1. What specific securities laws are involved?
    Violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Rule 10b-5.

  2. What is the typical consequence for securities fraud?
    Civil penalties, disgorgement of gains, injunctions, and disqualification from serving as an officer or director.

  3. Has the case reached a settlement?
    As of the latest update, no settlement has been publicly reported.

  4. Who are the other parties involved, if any?
    The SEC is the plaintiff; no other defendants or third parties have been publicly listed.

  5. What lessons can securities professionals derive from this case?
    Emphasize accuracy in disclosures, maintain thorough records, and avoid making statements that could be construed as misleading or false.


References

[1] U.S. Securities and Exchange Commission. (2018). Litigation Release No. 24598. Retrieved from https://www.sec.gov/litigation/litreleases/2018/lr24598.htm

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.